A Phase 1 study of AUBE00 in solid tumors

Recruiting Phase 1 NCT07030959

Study Description

A first-in-human study to evaluate the safety and effectiveness of an investigational drug called AUBE00 in patients with advanced solid tumors

Study Details

Registry ID:: NCT07030959
Conditions:: Solid Tumors
Phase:: Phase 1
Target Enrollment:: 130 participants
Start Date:: June 5, 2025
Age Range:: 18–999 years
Healthy Volunteers:: No

Study Locations (5 sites)

NEXT Oncology Virginia
Fairfax, VirginiaUnited States, United States
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, MichiganUnited States, United States
The University of Texas MD Anderson Cancer Center
Houston, TexasUnited States, United States
National Cancer Center Hospital
Chuo-ku, TokyoJapan, Japan
National Cancer Center Hospital East
Kashiwa, ChibaJapan, Japan

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →